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ADVERSE EFFECTS OF STATINS
Retraction of statins article is not in the public interest:
better characterisation of benefits and risks is crucial
Tom Fahey professor of general practice, Susan Smith associate professor of general practice
Royal College of Surgeons in Ireland Medical School, Dublin 2, Republic of Ireland
Abramson and colleagues highlight uncertainties about adverse
effects of statins for the primary prevention of cardiovascular
disease in patients at low absolute cardiovascular risk.1 2 There
is a substantial discrepancy between observational studies and
randomised controlled trials (RCTs) regarding the reporting of
adverse effects of statins. This could be the result of
under-reporting of “mild” adverse effects in RCTs or it could
be a true representation of the clinical picture. Our clinical
experience is that patients are reluctant to report adverse effects
and many discontinue treatment without saying so. A recent
systematic review confirms this—only 49% (95% CI 48.9% to
49.2%) of patients were adherent at one year on the basis of
observational data, whereas RCTs report that 90.3% (89.8% to
90.8%) continue to be adherent.3 RCTs of adherence enhancing
strategies show a substantial reduction in adherence (<50%)
between six and 24 months.4 Although adherence is only a
marker for adverse effects and patients discontinue for other
reasons, this problem needs to be further explored because poor
adherence is associated with increased cardiovascular mortality.5
The second uncertainty relates to individuals’ preferences to
take statins when their risk is less than 10% over 10 years.6 In
our RCT of a decision aid concerning risk and benefits of blood
pressure lowering treatment, a third of patients declined drug
treatment. Although National Institute for Health and Care
Excellence recommendations are lowering cardiovascular
treatment thresholds, individual patients’ preferences about the
benefits and risk of treatment differ. Correct characterisation of
the benefits and risks of statins is crucial to enabling informed
decision making.
The evidence on adverse effects and adherence to statins needs
further investigation. Retraction of this article is not in the public
interest.
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